This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Pyridorin in Patients With Diabetic Nephropathy

This study has been completed.
Information provided by:
BioStratum Identifier:
First received: April 27, 2006
Last updated: NA
Last verified: April 2006
History: No changes posted
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.

Condition Intervention Phase
Diabetic Nephropathy Drug: Pyridorin (pyridoxamine dihydrochloride) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by BioStratum:

Estimated Enrollment: 128
Study Start Date: October 2001
Estimated Study Completion Date: January 2003

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with type 1 or type 2 diabetes
  • Sitting blood pressure of <=170/100 mm Hg at weeks -2 and -1
  • Hemoglobin A1C <=12% at week -2
  • Patients with diagnosis of diabetic nephropathy as defined by

    1. Serum Creatinine <=2.0 mg/dL at weeks -2 and -1
    2. Urinary albumin excretion >=300 mg/24 hours at week -2
    3. Diagnosis of diabetic retinopathy
  • Creatinine clearance >=40 mL/min at weeks -2 and -1
  • Voluntary written consent to participate in this study

Exclusion Criteria:

  • History of allergic or adverse response to any B vitamin
  • History of major cardiovascular or cerebrovascular events
  • History of cancer except adequately treated basal or squamous cell carcinoma of the skin
  • History of diabetic ketoacidosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00320060

Sponsors and Collaborators
Study Director: Thorsten P Degenhardt, Ph.D. BioStratum, Inc.
  More Information Identifier: NCT00320060     History of Changes
Other Study ID Numbers: PYR-206
Study First Received: April 27, 2006
Last Updated: April 27, 2006

Keywords provided by BioStratum:
Diabetic nephropathy
Advanced Glycation Endproduct Inhibitor

Additional relevant MeSH terms:
Kidney Diseases
Diabetic Nephropathies
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on August 22, 2017